Immunic (Nasdaq: IMUX) to join investor conferences in March, focusing on oral therapies for neurologic and gastrointestinal diseases.On March 3, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech company specializing in advanced oral treatments for neurological and gastrointestinal conditions, revealed their involvement in investor conferences during March.
